Then your eyes stop on Section 5.3.4: "Cardiac Safety Findings." A new signal. In a parallel Phase II trial of the same compound -- different indication, different patient population -- three participants developed prolonged QTc intervals, and one experienced a cardiac arrhythmia requiring hospitalization. The sponsor has updated the IB to include QTc prolongation as a newly identified risk.

You have 35 participants actively enrolled. They are taking this drug right now. Every one of them sat across from you -- or from the investigator, or from a colleague on the research team -- and heard a description of the risks. That description did not include cardiac arrhythmia. It did not include QTc prolongation. It could not have, because the signal had not yet emerged.

Their consent was valid when they gave it. But it is no longer complete. And the gap between what they were told and what is now known -- that gap is your responsibility to close.

This is safety-driven reconsent. It is not the same as reconsenting for a protocol amendment that adds an MRI scan or extends the visit schedule. Those are logistical changes. This is different. This is telling a human being that the thing you put into their body carries a risk they did not know about when they agreed to take it. The urgency is different. The emotional stakes are different. The documentation requirements are more demanding. And the margin for error -- in your communication, in your timing, in your handling of the participant's response -- is narrower than in any other consent encounter you will face.

Then your eyes stop on Section 5.3.4: "Cardiac Safety Findings." A new signal. In a parallel Phase II trial of the same compound -- different indication, different patient population -- three participants developed prolonged QTc intervals, and one experienced a cardiac arrhythmia requiring hospitalization. The sponsor has updated the IB to include QTc prolongation as a newly identified risk.

You have 35 participants actively enrolled. They are taking this drug right now. Every one of them sat across from you -- or from the investigator, or from a colleague on the research team -- and heard a description of the risks. That description did not include cardiac arrhythmia. It did not include QTc prolongation. It could not have, because the signal had not yet emerged.

Their consent was valid when they gave it. But it is no longer complete. And the gap between what they were told and what is now known -- that gap is your responsibility to close.

This is safety-driven reconsent. It is not the same as reconsenting for a protocol amendment that adds an MRI scan or extends the visit schedule. Those are logistical changes. This is different. This is telling a human being that the thing you put into their body carries a risk they did not know about when they agreed to take it. The urgency is different. The emotional stakes are different. The documentation requirements are more demanding. And the margin for error -- in your communication, in your timing, in your handling of the participant's response -- is narrower than in any other consent encounter you will face.